ArQule, Inc. and Novartis Institutes for BioMedical Research, Inc. Initiate Chemistry Collaboration

05-Sep-2003
ArQule, Inc., a drug discovery and development company, today announced that it has entered into a chemistry collaboration with Novartis Institutes for BioMedical Research, Inc. (NIBRI), an affiliate of Novartis AG. As part of this collaboration, ArQule will apply its integrated chemistry technology platform to generate and optimize small-molecule compounds for NIBRI's anti-infective drug discovery program. The terms of the agreement were not disclosed. "The addition of Novartis, one of the world's leading R&D organizations, to our list of partners is further validation of our chemistry technologies business," said Dr. Stephen A. Hill, ArQule's President and Chief Executive Officer. "This announcement confirms our ability to add new customers for our chemistry services while continuing to build our internal proprietary portfolio of discovery and development programs."

Other news from the department science

Most read news

More news from our other portals

Discover the latest developments in battery technology!